Association of HIV diversity and survival in HIV-infected ugandan infants

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  James, Maria M ^a   Wang, Lei ^b   Musoke, Philippa ^c   Donnell, Deborah ^b   Fogel, Jessica ^a   Towler, William I ^a   Khaki, Leila ^a   Nakabiito, Clemensia ^c,d   Jackson, J Brooks ^a   Eshleman, Susan H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GAG1 PROTEIN; GAG2 PROTEIN; POL PROTEIN; UNCLASSIFIED DRUG; PRIMER DNA;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CHILD DEATH; CONTROLLED STUDY; DISEASE SEVERITY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HIGH RESOLUTION MELTING ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; UGANDA; VIRUS LOAD; VIRUS TYPING; CLASSIFICATION; NUCLEOTIDE SEQUENCE; SURVIVAL; VIROLOGY;

BASE SEQUENCE; DNA PRIMERS; HIV; HIV INFECTIONS; HUMANS; INFANT; SURVIVAL ANALYSIS; UGANDA; VIRAL LOAD;

EID: 79955025468     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018642     Document Type: Article

References (51)

1. World Health Organization (2008) Scale up of HIV-related prevention, diagnosis, care and treatment for infants and children. http://wwwwhoint/hiv/pub/paediatric/framework_2008/en/indexhtml: Accessed 12/10/2009.
2. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, et al. (2008) Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 359: 2233-2244.
3. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ, (2008) Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 8: 477-489.
4. Chilongozi D, Wang L, Brown L, Taha T, Valentine M, et al. (2008) Morbidity and mortality among a cohort of human immunodeficiency virus type 1-infected and uninfected pregnant women and their infants from Malawi, Zambia, and Tanzania. Pediatr Infect Dis J 27: 808-814.
5. Newell ML, Brahmbhatt H, Ghys PD, (2004) Child mortality and HIV infection in Africa: a review. AIDS 18 (Suppl 2): S27-34.
6. Obimbo EM, Wamalwa D, Richardson B, Mbori-Ngacha D, Overbaugh J, et al. (2009) Pediatric HIV-1 in Kenya: pattern and correlates of viral load and association with mortality. J Acquir Immune Defic Syndr 51: 209-215.
7. Shapiro RL, Lockman S, Kim S, Smeaton L, Rahkola JT, et al. (2007) Infant morbidity, mortality, and breast milk immunologic profiles among breast-feeding HIV-infected and HIV-uninfected women in Botswana. J Infect Dis 196: 562-569.
8. Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, et al. (2007) HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 195: 1177-1180.
9. Delwart EL, Pan H, Sheppard HW, Wolpert D, Neumann AU, et al. (1997) Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol 71: 7498-7508.
10. Mani I, Gilbert P, Sankale JL, Eisen G, Mboup S, et al. (2002) Intrapatient diversity and its correlation with viral setpoint in human immunodeficiency virus type 1 CRF02_A/G-IbNG infection. J Virol 76: 10745-10755.
11. Markham RB, Wang WC, Weisstein AE, Wang Z, Munoz A, et al. (1998) Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Natl Acad Sci U S A 95: 12568-12573.
12. Ross HA, Rodrigo AG, (2002) Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. J Virol 76: 11715-11720.
13. Sagar M, Lavreys L, Baeten JM, Richardson BA, Mandaliya K, et al. (2003) Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol 77: 12921-12926.
14. Joos B, Trkola A, Fischer M, Kuster H, Rusert P, et al. (2005) Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. J Virol 79: 9026-9037.
15. Verhofstede C, Demecheleer E, De Cabooter N, Gaillard P, Mwanyumba F, et al. (2003) Diversity of the human immunodeficiency virus type 1 (HIV-1) env sequence after vertical transmission in mother-child pairs infected with HIV-1 subtype A. J Virol 77: 3050-3057.
16. Leal E, Janini M, Diaz RS, (2007) Selective pressures of human immunodeficiency virus type 1 (HIV-1) during pediatric infection. Infect Genet Evol 7: 694-707.
17. Zhang H, Hoffmann F, He J, He X, Kankasa C, et al. (2006) Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology 3: 73.
18. Ganeshan S, Dickover RE, Korber BT, Bryson YJ, Wolinsky SM, (1997) Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease. J Virol 71: 663-677.
19. Strunnikova N, Ray SC, Livingston RA, Rubalcaba E, Viscidi RP, (1995) Convergent evolution within the V3 loop domain of human immunodeficiency virus type 1 in association with disease progression. J Virol 69: 7548-7558.
20. Halapi E, Leitner T, Jansson M, Scarlatti G, Orlandi P, et al. (1997) Correlation between HIV sequence evolution, specific immune response and clinical outcome in vertically infected infants. AIDS 11: 1709-1717.
21. Towler WI, James MM, Ray SC, Wang L, Donnell D, et al. (2010) Analysis of HIV diversity using a high resolution melting assay. AIDS Research and Human Retroviruses 26: 913-918.
22. Towler WI, Khaki L, James M, Musoke P, Coates T, et al. (2010) Use of a high-resolution melting (HRM) assay to evaluate HIV gag region diversity in HIV-infected adults with different stages of HIV infection. 17th Conf on Retroviruses and Opportunistic Infections San Francisco, CA,: Abstract # 267.
23. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, et al. (1999) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354: 795-802.
24. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, et al. (2003) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362: 859-868.
25. Church JD, Omer SB, Guay LA, Huang W, Lidstrom J, et al. (2008) Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis 198: 1075-1082.
26. Eshleman SH, Guay LA, Mwatha A, Brown ER, Cunningham SP, et al. (2004) Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 35: 126-130.
27. Herrmann MG, Durtschi JD, Wittwer CT, Voelkerding KV, (2007) Expanded instrument comparison of amplicon DNA melting analysis for mutation scanning and genotyping. Clin Chem 53: 1544-1548.
28. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, et al. (2005) Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 102: 18514-18519.
29. Mullins JI, Jensen MA, (2006) Evolutionary dynamics of HIV-1 and the control of AIDS. Curr Top Microbiol Immunol 299: 171-192.
30. Sagar M, Kirkegaard E, Lavreys L, Overbaugh J, (2006) Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. AIDS Res Hum Retroviruses 22: 430-437.
31. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, et al. (1999) Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73: 10489-10502.
32. Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, et al. (2010) Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 84: 6241-6247.
33. Keele BF, Derdeyn CA, (2009) Genetic and antigenic features of the transmitted virus. Curr Opin HIV AIDS 4: 352-357.
34. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7557.
35. Li H, Bar KJ, Wang S, Decker JM, Chen Y, et al. (2010) High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog 6: e1000890.
36. Long EM, Martin HL Jr, Kreiss JK, Rainwater SM, Lavreys L, et al. (2000) Gender differences in HIV-1 diversity at time of infection. Nat Med 6: 71-75.
37. Learn GH, Muthui D, Brodie SJ, Zhu T, Diem K, et al. (2002) Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol 76: 11953-11959.
38. Keele BF, (2010) Identifying and characterizing recently transmitted viruses. Curr Opin HIV AIDS 5: 327-334.
39. Baum LL, (2010) Role of humoral immunity in host defense against HIV. Curr HIV/AIDS Rep 7: 11-18.
40. Piantadosi A, Chohan B, Panteleeff D, Baeten JM, Mandaliya K, et al. (2009) HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response. AIDS 23: 579-587.
41. Liu S, Xing H, He X, Xin R, Zhang Y, et al. (2008) Dynamic analysis of genetic diversity of gag and env regions of HIV-1 CRF07_BC recombinant in intravenous drug users in Xinjiang Uvghur Autonomous Region, China. Arch Virol 153: 1233-1240.
42. Huang S, Dunkley-Thompson J, Tang Y, Macklin EA, Steel-Duncan J, et al. (2008) Deficiency of HIV-Gag-specific T cells in early childhood correlates with poor viral containment. J Immunol 181: 8103-8111.
43. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, et al. (1997) Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 336: 1337-1342.
44. World Health Organization (2009) Guidelines for HIV diagnosis and monitoring of antiretroviral therapy- Revised version 2009. http://2039070117/PDS_DOCS/B4375pdf: Accessed 8/3/2010.
45. Buseyne F, Blanche S, Schmitt D, Griscelli C, Riviere Y, (1993) Detection of HIV-specific cell-mediated cytotoxicity in the peripheral blood from infected children. J Immunol 150: 3569-3581.
46. Luzuriaga K, Koup RA, Pikora CA, Brettler DB, Sullivan JL, (1991) Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children. J Pediatr 119: 230-236.
47. Thobakgale CF, Ramduth D, Reddy S, Mkhwanazi N, de Pierres C, et al. (2007) Human immunodeficiency virus-specific CD8+ T-cell activity is detectable from birth in the majority of in utero-infected infants. J Virol 81: 12775-12784.
48. Panel on Antiretroviral Therapy and Medical Management of HIV-infectedChildren (2010) Guidelines for the use of antiretroviral agents in pediatric HIV infection. http://aidsinfonihgov/ContentFiles/PediatricGuidelinespdf: Accessed 9/2/2010.
49. Shalekoff S, Meddows-Taylor S, Gray GE, Sherman GG, Coovadia AH, et al. (2009) Identification of human immunodeficiency virus-1 specific CD8+ and CD4+ T cell responses in perinatally-infected infants and their mothers. AIDS 23: 789-798.
50. Frahm N, Brander C, (2007) HIV viral diversity and escape from cellular immunity. Curr Infect Dis Rep 9: 161-166.
51. Musoke PM, Barlow-Mosha L, Bagenda D, Mudiope P, Mubiru M, et al. (2009) Response to antiretroviral therapy in HIV-infected Ugandan children exposed and not exposed to single-dose nevirapine at birth. J Acquir Immune Defic Syndr 52: 560-568.